Figure 5

A CTHRC1-neutralizing antibody reduces tumor growth and infiltration of TEMs in pancreatic cancer. (a) CFPAC-1 cells stably expressing a firefly luciferase gene and a GFP gene were orthotopically injected into C57BL/6 mice (n=5). Five days after injection of the tumor cells, tumor-bearing mice were administered control IgG (5 mg kg⁻¹) or the CTHRC1-neutralizing antibody (5 mg kg⁻¹) intraperitoneally twice a week. In vivo tumor growth was monitored by measuring the total flux from bioluminescence imaging. Four weeks after the tumor challenge, the total flux on the left side of the body was measured. (b) Primary tumors derived from CFPAC-1 cells were used for immunofluorescence staining of CD31⁺ cells. CD31⁺ cells in the excised tumors were detected by immunofluorescence analysis using confocal microscopy. The bar graph shows the quantification of CD31⁺ cells in the experimental group tumors compared with that of the control group tumors. Data are reported as the mean±s.d. (*P<0.01 versus rCTHRC). (c) Primary tumors of CFPAC-1 were excised and stained for infiltrating TEMs using anti-F4/80 and anti-Tie2 antibodies. The bar graph shows the quantification of infiltrated TEMs in the experimental group tumors compared with that of the control group tumors. Data are reported as the mean±s.d. (*P<0.01 versus rCTHRC). CTHRC1, collagen triple-helix repeat-containing 1; Ig, immunoglobulin; rCTHRC, recombinant CTHRC.